USA: A new study published in the Journal of Diabetes and Its Complications suggests that tirzepatide, a novel dual ...

Findings showed weekly treatment with tirzepatide significantly reduced the risk of progression to type 2 diabetes by 94% (efficacy estimand; pooled doses of 5mg, 10mg, 15mg) compared with placebo ...

Findings at week 176 demonstrated that among patients treated with tirzepatide (efficacy estimand; pooled doses of 5mg, 10mg, 15mg), 98.8% remained diabetes free, corresponding to a 94% reduction ...

Tirzepatide also significantly reduced the onset of T2D, with only 1.3% of participants in the treatment groups developing T2D compared to 13.3% in the placebo group (hazard ratio = 0.07, P < 0.001).

A study published in eClinicalMedicine found that tirzepatide outperforms semaglutide in reducing the risk of type 2 diabetes and major cardiovascular events among individuals with obesity, with ...

A three-year study of tirzepatide – a medication approved in the US as Mounjaro for diabetes and Zepbound for weight loss – found that when adults who had prediabetes and obesity or overweight ...

Adults with prediabetes and overweight or obesity have a 94% lower risk for developing type 2 diabetes with the once-weekly GIP/GLP-1 dual agonist tirzepatide vs. placebo, according to top-line ...